Head-to-head · WeighScore
AM Rx vs Medsol RX
The verdict
Medsol RX takes it — 61/100 to 49.9/100.
Medsol RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medsol RX is a GLP-1 weight-loss telehealth program offering compounded semaglutide (from $209/mo) and tirzepatide, prescribed by board-certified clinicians via OpenLoop and shipped nationwide.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Medsol RX |
|---|---|---|
| WeighScore | 49.9/100 | 61/100 |
| Grade | C | C |
| Scorecard rank | #490 | #306 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $209/mo (compounded) |
| Tirzepatide | Not disclosed | $250/mo (compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #490 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #306 · C
Strengths
- Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
- Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
- Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
- Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons
Where it loses points
- Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
- No legal entity name published on the site
- Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
- Compounded GLP-1s are not FDA-approved (the site discloses this)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.